Table 3.
Prescription of medications that affect urinary stone recurrence during the first yr after incident stone diagnosis, among patients who completed at least one 24-h urine test, by geographic region
| Geographic Region | Thiazide Prescriptions | Alkali Prescriptions | Allopurinol Prescriptionsa | |||
|---|---|---|---|---|---|---|
| 24-h Urine Calcium >200 mg/d (n=5292) | 24-h Urine Citrate ≤400 mg/d (n=5433) | 24-h Urine Uric Acid >800 mg/d (n=601) | ||||
| Participants Receiving Medication during First Year after Diagnosis (N, %) | Difference from Baseline in Proportion of Participants Receiving Medication (%) | Participants Receiving Medication during First Year after Diagnosis (N, %) | Difference from Baseline in Proportion of Participants Receiving Medication (%) | Participants Receiving Medication during First Year after Diagnosis (N, %) | Difference from Baseline in Proportion of Participants Receiving Medication (%) | |
| Midwest | 424 (30%) | 15 | 559 (37%) | 29 | 97 (11%) | 6 |
| Northeast | 149 (25%) | 7 | 252 (35%) | 27 | 26 (6%) | 4b |
| Southeast | 353 (27%) | 10 | 545 (36%) | 26 | 78 (8%) | 4 |
| West | 536 (27%) | 11 | 643 (39%) | 32 | 79 (8%) | 3 |
All P values for changes in prescriptions were significant at <0.001 except where marked. All P values for differences in changes in prescriptions between regions were significant at <0.001.
a
Excluding patients with gout.
b
P value 0.009.